Cardium Reports On Applicability Of Corgentin To Stem Cell Therapies
Cardium Therapeutics (NYSE Amex: CXM) reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1–Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell Mobilization via Paracrine Activation of SDF-1 alpha/CXCR4 t
[Read the full article here]Related News:
Independent Studies Indicate That Ad5IGF-1 Potentiates Stem Cells To Improve Cardiac Function After Heart Attack
Cardium Reports on Applicability of Corgentin to Stem Cell
TLR4 Inhibits Mesenchymal Stem Cell STAT3 Activation and Thereby Exerts Deleterious …